Four Ways to Turn Disqualification Data into Action

Quoted on this wiki

Every place a page here uses this source, in the order the words come in it.

1. With the comparison in view, it becomes clear the disqualification rate is a function of how the protocol defines eligibility, not of who the patient population is. Recognizing that the disqualification rate reflects protocol design rather than patient population is a different conversation entirely, and DQA makes it possible to hold the conversation. Action 1: Eliminate Dead Ends The baseline requirement for any DQA-informed program is straightforward: no patient who engages with a clinical trial should reach a dead end. Yet in most recruitment systems, that is exactly what a disqualified patient encounters. A dead end is a failure of the patient experience and a waste of that investment. Eliminating dead ends means building structured pathways for every outcome. When a patient does not match one trial, they should be shown alternative trials within the same condition that may be a better fit. When there is no current match anywhere in the network, they should be offered enrollment in a sponsor-dedicated volunteer registry — not a passive database, but an active outreach asset that notifies patients when a relevant new trial opens or when a previously ineligible patient's circumstances may have changed. When a registry patient becomes newly relevant to a study that opens later, they re-enter the funnel with their prior eligibility profile already on record. This is the operational basis for a DQA-informed program. Every patient gets a meaningful next step: a matching trial, an alternative trial, registry enrollment, or some combination. Making that commitment does not require complex infrastructure; it requires a clear decision that disqualified patients are not the end of the conversation.  "Disqualified patients are not a failure to be minimized and moved past. Every patient who tried to qualify and didn't make it through left behind something useful." “When a patient calls back months after their initial disqualification — because they have finished a second-line treatment, because their disease has progressed, or because their circumstances have changed — that conversation is a referral in progress.” Action 3: Feed Insights Back to Study Teams DQA creates a feedback channel that most recruitment programs do not currently have: a structured, data-driven line of communication from real-world patient populations back to the study teams responsible for protocol design. That feedback channel is most valuable when the data is specific enough to support a substantive clinical conversation. If a treatment outcome requirement is consistently eliminating a large share of engaged patients across multiple sites and time periods, the question worth asking is whether that cutoff is scientifically necessary or whether it reflects an assumption that has not been revisited considering current patient populations. Questioning whether a protocol cutoff is scientifically necessary is a conversation DQA makes possible and defensible. Without structured, quantified disqualification data, it is very difficult to bring protocol discussions to study teams with credibility. With the appropriate data, the conversation shifts from anecdote to evidence. When the same disqualification pattern appears across multiple trials targeting the same indication, the interpretation changes further. A consistent pattern across studies is not a protocol-specific problem, it signifies a systemic population challenge that reframes how the indication as a whole is approached. This cross-trial, cross-condition intelligence is only visible when DQA is structured consistently and analyzed at scale. Action 4: Calibrate Upstream Outreach For pharma and biotech sponsors focused on demonstrating recruitment ROI, upstream outreach calibration is the most direct application of DQA intelligence. The logic is straightforward: if you know which eligibility criteria are responsible for the highest share of disqualifications in a clinical trial, you can work upstream, through paid media, HCP communications, and advocacy content, to set patient expectations before they invest time in the process.

   In Referral eligibility and qualification

2. “But the view is only valuable if it drives action.” Data from a global pharmaceutical sponsor's Phase 1 study for advanced solid tumors, which covered seven tumor types including colorectal, endometrial, gallbladder, kidney, lung, ovarian, and thyroid cancers, illustrates the point. The network recorded more than 6,400 completed questionnaires in the reporting period, with an overall match rate of approximately 50%. A 50% match rate means more than 3,000 patients who actively sought a clinical trial option did not qualify, and each of those disqualifications was categorized by the specific eligibility criterion that caused the failure. The match rate varied dramatically by condition, ranging from 9.8% for ovarian cancer to 67.6% for colorectal cancer. That variation is telling a specific story about each condition's patient population relative to the protocol's eligibility requirements, and it looks very different depending on which condition you examine. For lung cancer, the network saw 1,232 completed questionnaires with 620 patients matching (50.3%), leaving 612 patients who actively sought a lung cancer trial and did not qualify. The disqualification profile was spread across several criteria: primary diagnosis accounted for 44.7% of non-matches, metastatic status for 30.9%, and ECOG performance score for 15%. That distribution points to a population readiness challenge — patients seeking the trial represent a broad range of disease stages and functional statuses, and the protocol's eligibility window captures only a portion of that population. Ovarian cancer tells a completely different story. With 3,545 completed questionnaires and only 346 matches, the 9.8% match rate was the lowest across all seven tumor types. The driver was concentrated rather than distributed: 62% of unmatched ovarian cancer patients failed on primary diagnosis specificity, meaning the vast majority of ovarian cancer patients completing the questionnaire did not have the specific ovarian subtype the trial required.

   In Disqualification feedback loop

Quotes are verbatim and belong to their publishers. Where a quote has been translated, the original wording is kept below it.